1.
COVID-19 clinical trials: learning from exceptions in the research chaos
by Tikkinen, Kari A O
Nature medicine, 2020-11, Vol.26 (11), p.1671-1672
2.
A critique of the fragility index – Authors' reply
by Del Paggio, Joseph C
The lancet oncology, 2019-10, Vol.20 (10), p.e554-e554
3.
Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
by Boers, Maarten
Journal of clinical epidemiology, 2014, Vol.67 (7), p.745-753
4.
Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands
by van den Bogert, Cornelis A
Journal of clinical epidemiology, 2017, Vol.88, p.140-147
5.
Randomised clinical trial: low‐FODMAP rye bread vs. regular rye bread to relieve the symptoms of irritable bowel syndrome
by Laatikainen, R
Alimentary pharmacology & therapeutics, 2016-09, Vol.44 (5), p.460-470
7.
Minimally Invasive versus Open Distal Pancreatectomy: An Individual Patient Data Meta-Analysis of Two Randomized Controlled Trials
by Korrel, M
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2020-11, Vol.20, p.S186-S186
8.
Personalized 177.sup.Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
by Del Prete, Michela
European journal of nuclear medicine and molecular imaging, 2019-03-01, Vol.46 (3), p.728
9.
Response assessment criteria for brain metastases: proposal from the RANO group
by Lin, Nancy U, Dr
The lancet oncology, 2015, Vol.16 (6), p.e270-e278
10.
Exploring the ethical and regulatory issues in pragmatic clinical trials
by Califf, Robert M
Clinical trials (London, England), 2015-10, Vol.12 (5), p.436-441
11.
A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines
by Dal-Ré, Rafael
Journal of clinical epidemiology, 2019-10, Vol.114, p.60-71
12.
177.sup.Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
by Rahbar, Kambiz
European journal of nuclear medicine and molecular imaging, 2018-03-01, Vol.45 (3), p.513
13.
The global landscape of stem cell clinical trials
by Li, Matthew D
Regenerative medicine, 2014-01-01, Vol.9 (1), p.27-39
14.
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
by Cruz Rivera, Samantha
Nature medicine, 2020-09, Vol.26 (9), p.1351-1363
15.
Pathophysiology and clinical trials have limitations in some areas of medicine: focus on psychiatry (letter commenting: J Clin Epidemiol. 2014;67
by De Leon, Jose
Journal of clinical epidemiology, 2016-07-01, Vol.75, p.126
16.
Correction: S22 Bap1 expression and treatment outcomes in malignant pleural mesothelioma in a prospective uk based clinical trial
Thorax, 2018-06, Vol.73 (6), p.598-598
17.
How Good Is "Evidence" from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?
by Naci, Huseyin
Annual review of pharmacology and toxicology, 2015-01-06, Vol.55 (1), p.169-189
18.
Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials
by Carlisle, Benjamin
Clinical trials (London, England), 2015-02, Vol.12 (1), p.77-83
19.
Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients
by Calza, Leonardo
AIDS research and human retroviruses, 2017-07-01, Vol.33 (7), p.632-638
20.
